Table 2. Clinical characteristics of IgAN-SD patients with hump-like subepithelial deposits and diagnosed IgA-IRGN cases.
| Age | Sex | DM | Pre infect. |
Cr (mg/dL) |
C3 (mg/dL) |
C4 (mg/dL) |
U-pro (g/gCr) |
U-RBC /HPF |
Oxford classification | Neu |
IgA M |
IgA GBM |
C3 M |
C3 GBM |
λ-D | EDD locat. |
|||||
| M | E | S | T | C | |||||||||||||||||
| IgAN-SD with hump-shaped subepithelial deposits | |||||||||||||||||||||
| 1 | 18 | M | (-) | (+) | 0.8 | 88 | 18 | 1.8 | >100 | 0 | 0 | 0 | 1 | 1 | (-) | 3+ | 1+ | 2+ | 1+ | No | MEpEn |
| 2 | 22 | M | (-) | (+) | 0.7 | 34 | 38 | 0.1 | >100 | 1 | 0 | 0 | 0 | 0 | (-) | 1+ | - | 1+ | 1+ | No | MEp |
| 3 | 23 | M | (-) | (-) | 0.7 | 112 | 31 | 0.2 | 50–99 | 1 | 0 | 0 | 0 | 1 | (+) | 2+ | - | 1+ | - | Yes | MEp |
| 4 | 38 | F | (-) | (-) | 1.1 | 68 | 24 | 2.6 | 20–29 | 0 | 1 | 0 | 0 | 1 | (+) | 1+ | - | 2+ | 1+ | Yes | MEp |
| 5 | 39 | F | (-) | (-) | 0.7 | 41 | 16 | 1+*1 | 15–20 | 1 | 1 | 0 | 0 | 0 | (+) | 1+ | - | 1+ | - | No | MEp |
| 6 | 51 | F | (-) | (-) | 0.5 | 17 | 22 | -*1 | 20–29 | 1 | 0 | 0 | 1 | 0 | (+) | 1+ | - | 1+ | - | Yes | MEp |
| 7 | 61 | M | (+) | (-) | 1.1 | NA | NA | 2.0 | >100 | 1 | 0 | 0 | 1 | 2 | (-) | 1+ | - | 1+ | - | No | MEp |
| 8 | 75 | F | (-) | (+) | 0.6 | 81 | 17 | 8.3 | 1–4 | 1 | 1 | 0 | 0 | 0 | (+) | 1+ | - | - | - | No | MEpEn |
| 9 | 80 | M | (+) | (-) | 5.5 | 95 | 22 | 1.9 | >100 | 1 | 0 | 0 | 1 | 0 | (-) | 1+ | - | 1+ | - | Yes | MEp |
| Age | Sex | DM | Pre infect. |
Cr (mg/dL) |
C3 (mg/dL) |
C4 (mg/dL) |
U-pro (g/gCr) |
U-RBC /HPF |
Oxford classification | Neu |
IgA M |
IgA GBM |
C3 M |
C3 GBM |
λ-D | EDD locat. |
|||||
| M | E | S | T | C | |||||||||||||||||
| Cases diagnosed as IgA-IRGN | |||||||||||||||||||||
| 1 | 18 | M | (-) | (+) | 0.5 | 95 | 22 | 1.9 | >100 | 1 | 1 | 0 | 0 | 0 | (-) | 1+ | - | - | - | NA | MEpEn |
| 2 | 48 | M | (-) | (+) | 1.4 | NA | NA | 0.08 | 5–9 | 0 | 0 | 0 | 2 | 0 | (-) | 1+ | - | 1+ | - | NA | M |
| 3 | 79 | M | (-) | (+) | 3 | 73 | 21 | 1+*1 | >100 | 0 | 0 | 0 | 0 | 1 | (-) | 2+ | 2+ | 1+ | 2+ | No | MEpEn |
| 4 | 56 | M | (+) | (+) | 0.8 | 134 | 35 | 7.2 | >100 | 0 | 1 | 0 | 0 | 0 | (+) | 1+ | - | 1+ | - | NA | M |
| 5 | 69 | M | (-) | (+) | 3.7 | 124 | 32 | 3 | >100 | 1 | 1 | 0 | 1 | 1 | (+) | 1+ | - | 1+ | - | No | M |
| 6 | 60 | M | (+) | (+) | 4.79 | 115 | 35 | 6.4 | 11–20 | 0 | 1 | 0 | 0 | 1 | (+) | 1+ | - | 1+ | - | NA | MEpEn |
| 7 | 78 | M | (-) | (+) | 2.94 | 64 | 30 | 10.1 | 5–9 | 1 | 1 | 0 | 1 | 1 | (+) | 2+ | 1+ | 3+ | 2+ | No | NA |
Age: years, IgAN-SD: IgA nephropathy with subepithelial deposits, M: male, F: female, DM: diabetes mellitus, Pre infect.: histories of infection before biopsy written in renal biopsy request forms, Cr: serum creatinine (mg/dL), C3: serum C3 (mg/dL), C4: serum C4(mg/dL), U-Pro: protein-to-creatinine ratio (g/gCr), U-RBC: urinary sediment red blood cells/ high power field, M: Oxford classification M, E: Oxford classification E, S: Oxford classification S, T: Oxford classification T, C: Oxford classification C, Neu: neutrophil infiltration in capillary, IF IgA: intensity of immune fluorescence of IgA, IF C3: intensity of immune fluorescence of C3, λ-D: Lambda dominance in immune fluorescence, EDD locat.: Electron dense deposits location, M:mesangium Ep: subepithelial En: Subendothelial, SEnD: subendothelial deposits, NA: not available
*1 The results of quantitative urinary protein were not available